IRAK1

IRAK1
Identifiers
Aliases	IRAK1 , IRAK, pelle, interleukin 1 receptor associated kinase 1
External IDs	OMIM: 300283 MGI: 107420 HomoloGene: 37496 GeneCards: IRAK1
Gene location (Human) Chr. X chromosome (human) [1] Band Xq28 Start 154,010,506 bp [1] End 154,019,902 bp [1]
Gene location (Mouse) Chr. X chromosome (mouse) [2] Band X A7.3|X 37.61 cM Start 73,057,520 bp [2] End 73,067,524 bp [2]
RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in parotid gland pancreatic ductal cell endothelial cell periodontal fiber duodenum epithelium of esophagus stromal cell of endometrium kidney tubule superior surface of tongue appendix Top expressed in lacrimal gland parotid gland submandibular gland Paneth cell islet of Langerhans seminal vesicula body of femur substantia nigra cervix ciliary body More reference expression data BioGPS More reference expression data
Gene ontology Molecular function transferase activity protein kinase activity nucleotide binding heat shock protein binding protein homodimerization activity kinase activity NF-kappaB-inducing kinase activity protein binding protein heterodimerization activity ATP binding protein serine/threonine kinase activity Cellular component membrane lipid droplet plasma membrane endosome membrane interleukin-1 receptor complex nucleus cytoplasm cytosol Biological process cellular response to heat response to interleukin-1 positive regulation of MAP kinase activity regulation of cytokine-mediated signaling pathway phosphorylation cytokine-mediated signaling pathway immune system process human ageing negative regulation of apoptotic process activation of NF-kappaB-inducing kinase activity MyD88-dependent toll-like receptor signaling pathway toll-like receptor signaling pathway positive regulation of transcription, DNA-templated protein phosphorylation JNK cascade response to lipopolysaccharide transmembrane receptor protein serine/threonine kinase signaling pathway positive regulation of NF-kappaB transcription factor activity protein complex oligomerization positive regulation of I-kappaB kinase/NF-kappaB signaling protein autophosphorylation toll-like receptor 9 signaling pathway cellular response to lipopolysaccharide negative regulation of NF-kappaB transcription factor activity nucleotide-binding oligomerization domain containing signaling pathway positive regulation of type I interferon production cellular response to hypoxia lipopolysaccharide-mediated signaling pathway signal transduction positive regulation of smooth muscle cell proliferation toll-like receptor 4 signaling pathway toll-like receptor 2 signaling pathway innate immune response type I interferon signaling pathway viral process interleukin-1-mediated signaling pathway intracellular signal transduction positive regulation of NIK/NF-kappaB signaling positive regulation of leukocyte adhesion to vascular endothelial cell Sources:Amigo / QuickGO
Orthologs Species Human Mouse Entrez 3654 16179 Ensembl ENSG00000184216 ENSMUSG00000031392 UniProt P51617 Q62406 RefSeq (mRNA) NM_001025242 NM_001025243 NM_001569 NM_001177973 NM_001177974 NM_001177975 NM_001177976 NM_008363 RefSeq (protein) NP_001020413 NP_001020414 NP_001560 NP_001171444 NP_001171445 NP_001171446 NP_001171447 NP_032389 Location (UCSC) Chr X: 154.01 – 154.02 Mb Chr X: 73.06 – 73.07 Mb PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

Interleukin-1 receptor-associated kinase 1 (IRAK-1) is an enzyme in humans encoded by the IRAK1 gene. ^{[5] [6]} IRAK-1 plays an important role in the regulation of the expression of inflammatory genes by immune cells, such as monocytes and macrophages, which in turn help the immune system in eliminating bacteria, viruses, and other pathogens. IRAK-1 is part of the IRAK family consisting of IRAK-1, IRAK-2, IRAK-3, and IRAK-4, and is activated by inflammatory molecules released by signaling pathways during pathogenic attack. ^[7] IRAK-1 is classified as a kinase enzyme, which regulates pathways in both innate and adaptive immune systems. ^[8]

Structure

IRAK-1 contains an N-terminal death domain (DD), a ProST domain, a centrally located kinase domain, and a C-terminal domain. The DD on IRAK-1 acts as an interaction platform for other DD-containing protein, most notably the adaptor protein myeloid differentiation factor 88, MyD88.

The proST domain contains serine, proline, and threonine amino acid residues and is used to facilitate IRAK-1 interaction with other IRAK family members or proteins. For example, auto-phosphorylation may occur multiple times in the ProST domain, which allows IRAK-1 to dissociate from the MyD88 bound to the DD while maintaining interactions with downstream proteins such as TNF receptor-associated factor 6 (TRAF-6) to initiate further pathway signaling. ^[7]

Moreover, IRAK-1 contains an invariant lysine within the centrally located kinase domain. The invariant lysine acts as a binding site for ATP and a mediator for catalytic function and kinase activity. ^{[7] [9]}

IRAK-1 also contains a tyrosine residue (Tyr²⁶²) that conformationally changes the active site of the IRAK-1 by inhibiting the hydrophilic pocket behind the binding site and thereby allows the IRAK-1 to remain in an active state. For example, ATP binding to the IRAK-1 binding site can readily occur in the presence of Tyr²⁶⁶, because Tyr²⁶⁶ will occupy the hydrophilic pocket where ATP competitive inhibitors may bind and disrupt catalytic function. ^[7]

Activation

In the presence of foreign pathogens, IRAK-1 induced signaling pathways can be activated by Toll-like receptors (TLRs) or by interleukin-1 family receptors (IL-1R) in response. TLRs recognize pathogen-associated molecular patterns (PAMPs) expressed on bacteria and IL-1Rs recognize and bind pro-inflammatory cytokines of the IL-1 family. Both the TLR and IL-1R mediate a signaling cascade that involves MyD88 binding to the receptor, oligomerization of the MyD88, recruitment of IRAK-1 via the DD, multimerization of IRAK-1, and ultimately kinase activation and further downstream signaling. ^{[10] [7]}

IRAK-1 can also be activated upon interaction with other IRAK family members. IRAK-1 and IRAK-4 can activate each other by using the DD as a platform for MyD88. IRAK-4 first phosphorylates IRAK-1 which catalyzes an IRAK-1 auto-phosphorylation cascade, occurring in three steps. IRAK-1 is first phosphorylated at Thr209, causing a conformational change. Then, IRAK-1 is phosphorylated at Thr387 rendering IRAK-1 fully active. Finally, auto-phosphorylation at several residues in the proST region stimulates IRAK-1 release from the receptor complex. ^[7]

Function

The IRAK-1 encodes the interleukin-1 receptor-associated kinase 1, which is a serine-threonine protein kinase that is associated with the interleukin-1 receptor (IL1R) upon stimulation. IRAK-1 is required for pro-inflammatory cytokine production downstream of TLR and IL-1R signaling pathways. Moreover, IRAK-1 is responsible for IL1-induced up-regulation of the transcriptional factor NF-kappa B. Upon binding with its receptor, IRAK-1 becomes activated, as described in Activation, and then dissociates from its receptor complex. IRAK-1 dissociates from the receptor alongside of TRAF6 - a ubiquitin E3 ligase that intermediates between various types of receptors for exogenous or endogenous mediators and activation of transcriptional responses via NF-kappa B and MAPK pathways. ^[11] IRAK-1 and TRAF-6 then bind to TAK-1 binding protein-1 (TAB-1), followed by binding to transforming growth factor-β-activated kinase (TAK-1) and TAB-2, forming a new complex. This complex then translocates into the cytoplasm wherein it associates with ubiquitin ligases such as ubiquitin conjugating enzyme-13 UBC-13 and ubiquitin conjugating enzyme E2 variant-1(UEV-1a), leading to the ubiquitination and degradation of TRAF-6. TAK-1 is then activated and phosphorylation of the inhibitor of κB kinase (IKK) complex, consisting of IKKα, IKKβ, and IKKγ, occurs. MAPKs are also activated in the process. Finally, NF-κB is activated to regulate the transcription of pro-inflammatory genes. ^[7] Alternatively, IRAK-1 activation of the NF-κB pathway can be regulated by the ubiquitination of Lys¹³⁴ and Lys¹⁸⁰. ^{[12] [7]}

Alternatively spliced transcript variants encoding different isoforms have been found for the IRAK1 gene. ^[13] Currently, there are three differentially spliced variants of IRAK1 - IRAK1, IRAK1b, and IRAK1c. IRAK1 was observed to undergo sumoylation, promoting its translocation to the nucleus instead of the cytoplasm upon pathogenic attack. IRAK1c, notably, remains stable upon sumoylation, does not undergo modification under the same circumstances and localizes only to the cytoplasm. ^[14]

IRAK-1 kinase activity is not the sole protein involved in pro-inflammatory immune responses, however, it serves as an adaptor protein that effectively binds MyD88, IRAK-4, the toll-interacting proteins (TOLLIP) ^[15] together to form a complex that induces IL-1R-mediated NF-κB activation. ^{[15] [7]}

Signaling pathway of toll-like receptors. Dashed grey lines represent unknown associations

Regulation

IRAK-1 activity is regulated during its activation and function. Auto-phosphorylation plays a role in IRAK-1 activation (see Activation), and also mediates proteasome-mediated degradation which results in the loss of the IRAK1 protein. ^[16] Alternatively, IRAK-1 may be regulated on the transcriptional level. The IRAK-1b splice variant lacks kinase activity and is resistant to proteasome-mediated degradation. Moreover, IRAK-1c splice variant has a truncated and thus mutated sequence at the C-terminus of its kinase domain and acts a negative regulator of the TLR and IL-1R signaling pathways. ^{[7] [16]}

Interactions

IRAK1 has been shown to interact with the following proteins:

• CHUK ^{[17] [18]}
• IKBKG ^{[17] [19]}
• IKK2, ^{[17] [18]}
• Myd88 ^{[20] [21] [22] [23]}
• NEMO ^[24]
• SOCS1 ^[24]
• STAT3 ^[24]
• TRAF6 ^{[21] [22] [5] [25] [26] [27] [28] [29] [30]}
• UBC, ^{[17] [19] [31] [32]}
• TOLLIP ^[33]
• TLR4 ^[34]

Clinical significance

IRAK-1 signaling is involved in rheumatoid arthritis. ^{[35] [36]} Moreover, IRAK-1 plays a significant role in cancer.

References

1. GRCh38: Ensembl release 89: ENSG00000184216 - Ensembl, May 2017
2. GRCm38: Ensembl release 89: ENSMUSG00000031392 - Ensembl, May 2017
3. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
4. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
5. Muzio M, Ni J, Feng P, Dixit VM (November 1997). "IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling". Science. 278 (5343): 1612–1615. Bibcode:1997Sci...278.1612M. doi:10.1126/science.278.5343.1612. PMID   9374458.
6. Cao Z, Henzel WJ, Gao X (February 1996). "IRAK: a kinase associated with the interleukin-1 receptor". Science. 271 (5252): 1128–1131. Bibcode:1996Sci...271.1128C. doi:10.1126/science.271.5252.1128. PMID   8599092. S2CID   42977425.
7. Jain A, Kaczanowska S, Davila E (2014). "IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance". Frontiers in Immunology. 5: 553. doi: 10.3389/fimmu.2014.00553 . PMC   4233944 . PMID   25452754.
8. Deng Y, Hahn BH, Tsao BP (2013). "Systemic Lupus Erythematosus". Emery and Rimoin's Principles and Practice of Medical Genetics: 1–22. doi:10.1016/B978-0-12-383834-6.00081-1. ISBN   9780123838346.
9. Wang Z, Wesche H, Stevens T, Walker N, Yeh WC (May 2009). "IRAK-4 inhibitors for inflammation". Current Topics in Medicinal Chemistry. 9 (8): 724–737. doi:10.2174/156802609789044407. PMC   3182414 . PMID   19689377.
10. Wang L, Qiao Q, Ferrao R, Shen C, Hatcher JM, Buhrlage SJ, et al. (December 2017). "Crystal structure of human IRAK1". Proceedings of the National Academy of Sciences of the United States of America. 114 (51): 13507–13512. Bibcode:2017PNAS..11413507W. doi: 10.1073/pnas.1714386114 . PMC   5754798 . PMID   29208712.
11. Dainichi T, Matsumoto R, Mostafa A, Kabashima K (2019). "Immune Control by TRAF6-Mediated Pathways of Epithelial Cells in the EIME (Epithelial Immune Microenvironment)". Frontiers in Immunology. 10: 1107. doi: 10.3389/fimmu.2019.01107 . PMC   6532024 . PMID   31156649.
12. Kong F, Liu Z, Jain VG, Shima K, Suzuki T, Muglia LJ, et al. (November 2017). "Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages". Journal of Immunology. 199 (10): 3654–3667. doi:10.4049/jimmunol.1700443. PMC   5672817 . PMID   29038250.
13. "Entrez Gene: IRAK1 interleukin-1 receptor-associated kinase 1".
14. Su J, Richter K, Zhang C, Gu Q, Li L (February 2007). "Differential regulation of interleukin-1 receptor associated kinase 1 (IRAK1) splice variants". Molecular Immunology. 44 (5): 900–905. doi:10.1016/j.molimm.2006.03.021. PMID   16690127.
15. "TOLLIP toll interacting protein [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2022-03-05.
16. Gottipati S, Rao NL, Fung-Leung WP (February 2008). "IRAK1: a critical signaling mediator of innate immunity". Cellular Signalling. 20 (2): 269–276. doi:10.1016/j.cellsig.2007.08.009. PMID   17890055.
17. Windheim M, Stafford M, Peggie M, Cohen P (March 2008). "Interleukin-1 (IL-1) induces the Lys63-linked polyubiquitination of IL-1 receptor-associated kinase 1 to facilitate NEMO binding and the activation of IkappaBalpha kinase". Molecular and Cellular Biology. 28 (5): 1783–1791. doi:10.1128/MCB.02380-06. PMC   2258775 . PMID   18180283.
18. Vig E, Green M, Liu Y, Yu KY, Kwon HJ, Tian J, et al. (March 2001). "SIMPL is a tumor necrosis factor-specific regulator of nuclear factor-kappaB activity". The Journal of Biological Chemistry. 276 (11): 7859–7866. doi: 10.1074/jbc.M010399200 . PMID   11096118.
19. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD (May 2008). "Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- and toll-like receptor-mediated NF-kappaB activation". Molecular and Cellular Biology. 28 (10): 3538–3547. doi:10.1128/MCB.02098-07. PMC   2423148 . PMID   18347055.
20. Chen BC, Wu WT, Ho FM, Lin WW (July 2002). "Inhibition of interleukin-1beta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88". The Journal of Biological Chemistry. 277 (27): 24169–24179. doi: 10.1074/jbc.M106014200 . PMID   11976320.
21. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z (July 1999). "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family". The Journal of Biological Chemistry. 274 (27): 19403–19410. doi: 10.1074/jbc.274.27.19403 . PMID   10383454.
22. Li S, Strelow A, Fontana EJ, Wesche H (April 2002). "IRAK-4: a novel member of the IRAK family with the properties of an IRAK-kinase". Proceedings of the National Academy of Sciences of the United States of America. 99 (8): 5567–5572. Bibcode:2002PNAS...99.5567L. doi: 10.1073/pnas.082100399 . PMC   122810 . PMID   11960013.
23. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al. (September 2001). "Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction". Nature. 413 (6851): 78–83. Bibcode:2001Natur.413...78F. doi:10.1038/35092578. PMID   11544529. S2CID   4333764.
24. "IRAK1 Gene | IRAK1 Protein | IRAK1 Antibody". GeneCards Human Gene Database.
25. Qian Y, Commane M, Ninomiya-Tsuji J, Matsumoto K, Li X (November 2001). "IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B". The Journal of Biological Chemistry. 276 (45): 41661–41667. doi: 10.1074/jbc.M102262200 . PMID   11518704.
26. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV (October 1996). "TRAF6 is a signal transducer for interleukin-1". Nature. 383 (6599): 443–446. Bibcode:1996Natur.383..443C. doi:10.1038/383443a0. PMID   8837778. S2CID   4269027.
27. Takatsuna H, Kato H, Gohda J, Akiyama T, Moriya A, Okamoto Y, et al. (April 2003). "Identification of TIFA as an adapter protein that links tumor necrosis factor receptor-associated factor 6 (TRAF6) to interleukin-1 (IL-1) receptor-associated kinase-1 (IRAK-1) in IL-1 receptor signaling". The Journal of Biological Chemistry. 278 (14): 12144–12150. doi: 10.1074/jbc.M300720200 . PMID   12566447.
28. Ling L, Goeddel DV (August 2000). "T6BP, a TRAF6-interacting protein involved in IL-1 signaling". Proceedings of the National Academy of Sciences of the United States of America. 97 (17): 9567–9572. Bibcode:2000PNAS...97.9567L. doi: 10.1073/pnas.170279097 . PMC   16905 . PMID   10920205.
29. Takaesu G, Ninomiya-Tsuji J, Kishida S, Li X, Stark GR, Matsumoto K (April 2001). "Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway". Molecular and Cellular Biology. 21 (7): 2475–2484. doi:10.1128/MCB.21.7.2475-2484.2001. PMC   86880 . PMID   11259596.
30. Chen F, Du Y, Zhang Z, Chen G, Zhang M, Shu HB, et al. (April 2008). "Syntenin negatively regulates TRAF6-mediated IL-1R/TLR4 signaling". Cellular Signalling. 20 (4): 666–674. doi:10.1016/j.cellsig.2007.12.002. PMID   18234474. S2CID   28812149.
31. Newton K, Matsumoto ML, Wertz IE, Kirkpatrick DS, Lill JR, Tan J, et al. (August 2008). "Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies". Cell. 134 (4): 668–678. doi: 10.1016/j.cell.2008.07.039 . PMID   18724939.
32. Xiao H, Qian W, Staschke K, Qian Y, Cui G, Deng L, et al. (May 2008). "Pellino 3b negatively regulates interleukin-1-induced TAK1-dependent NF kappaB activation". The Journal of Biological Chemistry. 283 (21): 14654–14664. doi: 10.1074/jbc.M706931200 . PMC   2386918 . PMID   18326498.
33. Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, et al. (June 2000). "Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor". Nature Cell Biology. 2 (6): 346–351. doi:10.1038/35014038. PMID   10854325. S2CID   32036101.
34. He X, Jing Z, Cheng G (2014). "MicroRNAs: new regulators of Toll-like receptor signalling pathways". BioMed Research International. 2014: 945169. doi: 10.1155/2014/945169 . PMC   3977468 . PMID   24772440.
35. "IRAK1 gene". Genetics Home Reference. U.S. National Library of Medicine. Archived from the original on 20 February 2017.
36. Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A (September 2018). "Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy". Oncotarget. 9 (70): 33416–33439. doi:10.18632/oncotarget.26058. PMC   6161786 . PMID   30279971.

Further reading

• Auron PE (1999). "The interleukin 1 receptor: ligand interactions and signal transduction". Cytokine & Growth Factor Reviews. 9 (3–4): 221–237. doi:10.1016/S1359-6101(98)00018-5. PMID   9918122.
• Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV (October 1996). "TRAF6 is a signal transducer for interleukin-1". Nature. 383 (6599): 443–446. Bibcode:1996Natur.383..443C. doi:10.1038/383443a0. PMID   8837778. S2CID   4269027.
• Brenner V, Nyakatura G, Rosenthal A, Platzer M (August 1997). "Genomic organization of two novel genes on human Xq28: compact head to head arrangement of IDH gamma and TRAP delta is conserved in rat and mouse". Genomics. 44 (1): 8–14. doi:10.1006/geno.1997.4822. PMID   9286695.
• Huang J, Gao X, Li S, Cao Z (November 1997). "Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein". Proceedings of the National Academy of Sciences of the United States of America. 94 (24): 12829–12832. Bibcode:1997PNAS...9412829H. doi: 10.1073/pnas.94.24.12829 . PMC   24223 . PMID   9371760.
• Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A (June 1998). "The human toll signaling pathway: divergence of nuclear factor kappaB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6)". The Journal of Experimental Medicine. 187 (12): 2097–2101. doi:10.1084/jem.187.12.2097. PMC   2212359 . PMID   9625770.
• Maschera B, Ray K, Burns K, Volpe F (April 1999). "Overexpression of an enzymically inactive interleukin-1-receptor-associated kinase activates nuclear factor-kappaB". The Biochemical Journal. 339 (2): 227–231. doi:10.1042/0264-6021:3390227. PMC   1220149 . PMID   10191251.
• Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z (July 1999). "IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family". The Journal of Biological Chemistry. 274 (27): 19403–19410. doi: 10.1074/jbc.274.27.19403 . PMID   10383454.
• Yang RB, Mark MR, Gurney AL, Godowski PJ (July 1999). "Signaling events induced by lipopolysaccharide-activated toll-like receptor 2". Journal of Immunology. 163 (2): 639–643. doi: 10.4049/jimmunol.163.2.639 . PMID   10395652.
• Thomas JA, Allen JL, Tsen M, Dubnicoff T, Danao J, Liao XC, et al. (July 1999). "Impaired cytokine signaling in mice lacking the IL-1 receptor-associated kinase". Journal of Immunology. 163 (2): 978–984. doi: 10.4049/jimmunol.163.2.978 . PMID   10395695.
• Reichwald K, Thiesen J, Wiehe T, Weitzel J, Poustka WA, Rosenthal A, et al. (March 2000). "Comparative sequence analysis of the MECP2-locus in human and mouse reveals new transcribed regions". Mammalian Genome. 11 (3): 182–190. doi:10.1007/s003350010035. PMID   10723722. S2CID   15901911.
• Burns K, Clatworthy J, Martin L, Martinon F, Plumpton C, Maschera B, et al. (June 2000). "Tollip, a new component of the IL-1RI pathway, links IRAK to the IL-1 receptor". Nature Cell Biology. 2 (6): 346–351. doi:10.1038/35014038. PMID   10854325. S2CID   32036101.
• Böl G, Kreuzer OJ, Brigelius-Flohé R (July 2000). "Translocation of the interleukin-1 receptor-associated kinase-1 (IRAK-1) into the nucleus". FEBS Letters. 477 (1–2): 73–78. doi: 10.1016/S0014-5793(00)01759-2 . PMID   10899313.
• Hartley JL, Temple GF, Brasch MA (November 2000). "DNA cloning using in vitro site-specific recombination". Genome Research. 10 (11): 1788–1795. doi:10.1101/gr.143000. PMC   310948 . PMID   11076863.
• Vig E, Green M, Liu Y, Yu KY, Kwon HJ, Tian J, et al. (March 2001). "SIMPL is a tumor necrosis factor-specific regulator of nuclear factor-kappaB activity". The Journal of Biological Chemistry. 276 (11): 7859–7866. doi: 10.1074/jbc.M010399200 . PMID   11096118.
• Li X, Commane M, Jiang Z, Stark GR (April 2001). "IL-1-induced NFkappa B and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK)". Proceedings of the National Academy of Sciences of the United States of America. 98 (8): 4461–4465. Bibcode:2001PNAS...98.4461L. doi: 10.1073/pnas.071054198 . PMC   31857 . PMID   11287640.
• Jensen LE, Whitehead AS (August 2001). "IRAK1b, a novel alternative splice variant of interleukin-1 receptor-associated kinase (IRAK), mediates interleukin-1 signaling and has prolonged stability". The Journal of Biological Chemistry. 276 (31): 29037–29044. doi: 10.1074/jbc.M103815200 . PMID   11397809.
• Qian Y, Commane M, Ninomiya-Tsuji J, Matsumoto K, Li X (November 2001). "IRAK-mediated translocation of TRAF6 and TAB2 in the interleukin-1-induced activation of NFkappa B". The Journal of Biological Chemistry. 276 (45): 41661–41667. doi: 10.1074/jbc.M102262200 . PMID   11518704.